Delcath Systems, Inc. (NASDAQ:DCTH) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $23.17.

Several equities analysts have recently weighed in on the stock. Weiss Ratings raised shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. BTIG Research upped their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Zacks Research raised shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a research report on Friday, August 7th.

Hedge Funds Weigh In On Delcath Systems

A number of large investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC bought a new stake in Delcath Systems in the 2nd quarter valued at $48,000. IFP Advisors Inc bought a new position in Delcath Systems during the 2nd quarter worth $52,000. Royal Bank of Canada lifted its holdings in shares of Delcath Systems by 14.8% during the first quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after buying an additional 2,364 shares in the last quarter. Leonteq Securities AG acquired a new stake in shares of Delcath Systems during the fourth quarter worth $293,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Delcath Systems in the first quarter valued at about $306,000. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Trading Up 0.8%

DCTH stock opened at $16.08 on Friday. The firm has a market capitalization of $557.98 million, a PE ratio of 1,609.61 and a beta of 0.57. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $17.42. The business’s 50 day simple moving average is $15.31 and its 200 day simple moving average is $12.52.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%.The business had revenue of $29.13 million for the quarter, compared to analysts’ expectations of $26.25 million. As a group, sell-side analysts predict that Delcath Systems will post -0.17 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc (NASDAQ:DCTH) is an oncology company focused on developing and commercializing liver-directed therapies for patients with primary and metastatic cancers of the liver. Its technology is designed to deliver high concentrations of chemotherapy to the liver while limiting systemic exposure.

The company’s primary product is the HEPZATO KIT, a combination of melphalan hydrochloride and the Hepatic Delivery System. The treatment is used to perform percutaneous hepatic perfusion, a procedure in which the liver is temporarily isolated so chemotherapy can be administered directly to it and then filtered before the blood returns to the patient’s circulation.